Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
EWING, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President […]
Peak Resorts Completes Acquisition of Snow Time
Adds Three Popular Pennsylvania Resorts to Growing Northeast Portfolio Snow Time Season Pass Upgrade Results Demonstrate the Strong Appeal of the […]
TSX News -
CN’s Ruest Named Railroader of the Year
MONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) — Today, Railway Age announced that the 56th annual recipient of the Railroader of […]
REPEAT – Premier Health Group Inc. Provides Update on Expansion into Cannabis Clinic for Patients
VANCOUVER, British Columbia, Nov. 26, 2018 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” […]
Resonant Inc. Initiates $4 Million Stock Repurchase Program
GOLETA, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, […]
TSX News -
Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
SAN DIEGO and TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company […]
Zafgen Provides Update on Investigational New Drug Application for ZGN-1061
BOSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) — Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems […]
Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development […]
Study Supports Valeritas’ V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm
BRIDGEWATER, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) — Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of […]
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
– Primary endpoint achieved with both EPIDIOLEX doses compared to placebo – – Today’s data represents the fourth positive Phase […]
